Kos Pharmaceuticals, Inc (KOSP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	5/8/2006 3:30:32 AM
	of 118

Skyepharma, Kos agree marketing, distribution deal for Flutiform in US LONDON (AFX) - Skyepharma PLC said it has entered into an agreement with Kos Pharmaceuticals Inc (NASDAQ: KOSP - news) for the marketing and distribution of its asthma and pulmonary disease treatment Flutiform in the United States. Kos will have exclusive rights to market Flutiform in the US and a right of first negotiation in Canada. SkyePharma (LSE: SKP.L - news) said it could receive up to 165 mln usd in milestone payments from the deal on achievement of all regulatory and revenue targets, of which 25 mln usd has been paid upfront. har

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next